• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

N-乙酰半胱氨酸治疗 COVID-19 的潜在机制。

The Potential Mechanism of N-acetylcysteine in Treating COVID-19.

机构信息

Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

The Second People's Hospital of Yichang, Yichang 443000, China.

出版信息

Curr Pharm Biotechnol. 2021;22(12):1584-1590. doi: 10.2174/1389201021999201228212043.

DOI:10.2174/1389201021999201228212043
PMID:33371832
Abstract

N-Acetylcysteine (NAC) has been proposed to be used to treat Coronavirus Disease 2019 (COVID-19). By reviewing the existing pathological studies of COVID-19, it was found that abundant mucus secretion, formation of a hyaline membrane (supportive of acute respiratory distress syndrome), and interstitial fibrous exudation may be important characteristics of COVID-19 and pathological targets of drug therapy. In addition, multiple extrapulmonary organ injuries in COVID- 19 may be associated with cytokine storm. NAC is an important antioxidant and anti-inflammatory drug. NAC has been demonstrated to have mucolytic effects in bronchitis, relieve respiratory failure in acute respiratory distress syndrome, and inhibit fibrous exudation in interstitial lung disease in clinical studies. These findings suggest that NAC may have a therapeutic effect on the pathological targets of COVID-19. Furthermore, NAC decreases TNF-α, IL-1β, IL-6, IL-8, IL-10, and IL-17 serum levels in patients with sepsis, severe burns, acute liver failure, or peritoneal dialysis and may also reduce cytokine storm in COVID-19. The antiviral effect of NAC on other respiratory viruses may also benefit COVID-19 patients. Summarizing the potential mechanisms of NAC in treating COVID-19 suggests that the role of NAC in COVID-19 treatment is worthy of further research.

摘要

N-乙酰半胱氨酸(NAC)已被提议用于治疗 2019 年冠状病毒病(COVID-19)。通过对 COVID-19 的现有病理研究进行回顾,发现大量黏液分泌、透明膜形成(支持急性呼吸窘迫综合征)和间质纤维渗出可能是 COVID-19 的重要特征和药物治疗的病理靶点。此外,COVID-19 中的多个肺外器官损伤可能与细胞因子风暴有关。NAC 是一种重要的抗氧化剂和抗炎药物。在临床研究中,NAC 已被证明具有支气管炎的黏液溶解作用,可缓解急性呼吸窘迫综合征中的呼吸衰竭,并抑制间质性肺病中的纤维渗出。这些发现表明,NAC 可能对 COVID-19 的病理靶点具有治疗作用。此外,NAC 可降低败血症、严重烧伤、急性肝衰竭或腹膜透析患者的 TNF-α、IL-1β、IL-6、IL-8、IL-10 和 IL-17 血清水平,也可能减轻 COVID-19 中的细胞因子风暴。NAC 对其他呼吸道病毒的抗病毒作用也可能使 COVID-19 患者受益。总结 NAC 治疗 COVID-19 的潜在机制表明,NAC 在 COVID-19 治疗中的作用值得进一步研究。

相似文献

1
The Potential Mechanism of N-acetylcysteine in Treating COVID-19.N-乙酰半胱氨酸治疗 COVID-19 的潜在机制。
Curr Pharm Biotechnol. 2021;22(12):1584-1590. doi: 10.2174/1389201021999201228212043.
2
N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions.N-乙酰半胱氨酸预防和治疗 COVID-19:现有证据和未来方向。
J Infect Public Health. 2022 Dec;15(12):1477-1483. doi: 10.1016/j.jiph.2022.11.009. Epub 2022 Nov 12.
3
N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.N-乙酰半胱氨酸:一种治疗 SARS-CoV-2 的潜在药物。
Med Hypotheses. 2020 Oct;143:109862. doi: 10.1016/j.mehy.2020.109862. Epub 2020 May 30.
4
Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.N-乙酰半胱氨酸 (NAC) 在预防 COVID-19 细胞因子风暴中的治疗潜力:当前证据综述。
Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2802-2807. doi: 10.26355/eurrev_202103_25442.
5
Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.使用 N-乙酰半胱氨酸预防和辅助治疗 COVID-19 的理由。
FASEB J. 2020 Oct;34(10):13185-13193. doi: 10.1096/fj.202001807. Epub 2020 Aug 11.
6
Oral high-dose acetylcysteine: Effective against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?口服大剂量乙酰半胱氨酸:对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)奥密克戎变异株有效?
Drug Discov Ther. 2022 Jul 20;16(3):139-141. doi: 10.5582/ddt.2022.01032. Epub 2022 May 6.
7
A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome.静脉注射 N-乙酰半胱氨酸治疗轻中度 COVID19 相关急性呼吸窘迫综合征患者的初步研究。
Pharmacol Rep. 2021 Dec;73(6):1650-1659. doi: 10.1007/s43440-021-00296-2. Epub 2021 Jun 10.
8
Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model.N-乙酰半胱氨酸(NAC)在治疗和/或管理仓鼠模型中 SARS-CoV-2 诱导的肺损伤中的治疗作用。
Eur J Pharmacol. 2023 Jan 5;938:175392. doi: 10.1016/j.ejphar.2022.175392. Epub 2022 Nov 15.
9
Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19?我们在使用 N-乙酰半胱氨酸作为 COVID-19 的预防和辅助治疗方面进展如何?
Eur Rev Med Pharmacol Sci. 2022 Jan;26(2):715-721. doi: 10.26355/eurrev_202201_27898.
10
Intravenous N-Acetylcysteine in Management of COVID-19: A Case Series.静脉注射 N-乙酰半胱氨酸治疗 COVID-19:病例系列。
J Pharm Pract. 2023 Aug;36(4):1008-1014. doi: 10.1177/08971900221080283. Epub 2022 Mar 24.

引用本文的文献

1
Development of an inhalable dry powder formulation for inhibition of SARS-CoV-2.一种用于抑制新型冠状病毒(SARS-CoV-2)的可吸入干粉制剂的研发。
Int J Pharm X. 2025 Jun 14;10:100346. doi: 10.1016/j.ijpx.2025.100346. eCollection 2025 Dec.
2
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.评价口服 N-乙酰半胱氨酸在接受常规抗病毒和羟氯喹方案治疗的 COVID-19 患者中的疗效和安全性:一项随机对照临床试验。
Immun Inflamm Dis. 2023 Nov;11(11):e1083. doi: 10.1002/iid3.1083.
3
The Problem of Home Therapy during COVID-19 Pandemic in Italy: Government Guidelines versus Freedom of Cure?
意大利新冠疫情期间的家庭治疗问题:政府指导方针与治疗自由?
J Pharm Pharmacol Res. 2022 Aug 2;6(3):100-114. doi: 10.26502/fjppr.055.
4
Management of hypoxemia in SARS-CoV-2 infection: Lessons learned from one year of experience, with a special focus on silent hypoxemia.新型冠状病毒2型感染中低氧血症的管理:从一年经验中吸取的教训,特别关注隐性低氧血症。
J Intensive Med. 2021 Mar 9;1(1):26-30. doi: 10.1016/j.jointm.2021.02.001. eCollection 2021 Jul.
5
Nutritional deficiencies that may predispose to long COVID.可能导致长新冠的营养缺乏。
Inflammopharmacology. 2023 Apr;31(2):573-583. doi: 10.1007/s10787-023-01183-3. Epub 2023 Mar 15.
6
Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials.免疫调节和/或抗炎药物治疗自闭症谱系障碍个体的核心症状和相关症状:随机、安慰剂对照试验的叙述性综述。
CNS Drugs. 2023 Mar;37(3):215-229. doi: 10.1007/s40263-023-00993-x. Epub 2023 Mar 13.
7
N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions.N-乙酰半胱氨酸预防和治疗 COVID-19:现有证据和未来方向。
J Infect Public Health. 2022 Dec;15(12):1477-1483. doi: 10.1016/j.jiph.2022.11.009. Epub 2022 Nov 12.
8
Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model.N-乙酰半胱氨酸(NAC)在治疗和/或管理仓鼠模型中 SARS-CoV-2 诱导的肺损伤中的治疗作用。
Eur J Pharmacol. 2023 Jan 5;938:175392. doi: 10.1016/j.ejphar.2022.175392. Epub 2022 Nov 15.
9
The Role of Antioxidant Agent (N-Acetylcysteine) in Oleic Acid-Induced Acute Lung Injury in a Rat Model.抗氧化剂(N-乙酰半胱氨酸)在油酸诱导的大鼠急性肺损伤模型中的作用
Cureus. 2022 Sep 23;14(9):e29478. doi: 10.7759/cureus.29478. eCollection 2022 Sep.
10
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体、当前的新冠疫苗及其对2019冠状病毒病(COVID-19)的治疗意义
Vaccines (Basel). 2022 Sep 16;10(9):1538. doi: 10.3390/vaccines10091538.